

## UNITED STATES DEPARTMENT OF COMMERCE **Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAM	ED INVENTOR	A	ITORNEY DOCKET	10.
09/533,219	03/23/00	KUKKOLA		P		
Γ			一	EX	XAMINER	
001095		HM22/0817	,			
THOMAS HOXI	E			TRUDNG.	T	
NOVARTIS CO	RPORATION			ART UNIT	PAPER NUMB	ER
PATENT AND	TRADEMARK D	FPT				
564 MORRIS	AVENUE			1624		15
SUMMIT NJ 0						'
SOMETT MA O	/201-107/			DATE MAILED:		
					08/17/01	

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

•							
Office Action Summary		Application No.	Applicant(s)				
		09/533,219	KUKKOLA, PAIVI JANNA				
		Examiner	Art Unit				
<u>-</u>		Tamthom N. Truong	1624				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status							
1)⊠	Responsive to communication(s) filed on <u>12 June 2001</u> .						
2a) <u></u> □	This action is <b>FINAL</b> . 2b)⊠ This action is non-final.						
3)□	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Dispositi	on of Claims						
4) 🖂	4) Claim(s) 9,11,12,14,16-19,21 and 22 is/are pending in the application.						
•	4a) Of the above claim(s) is/are withdrawn from consideration.						
5) 🗌	) Claim(s) is/are allowed.						
6)⊠	6)⊠ Claim(s) <u>9, 11, 12, 14, 16-19, 21, and 22</u> is/are rejected.						
7) 🗌	Claim(s) is/are objected to.						
8)□	Claim(s) are subject to restriction and/or	r election requirement.					
Application Papers							
9) The specification is objected to by the Examiner.							
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12)☐ The oath or declaration is objected to by the Examiner.							
_	nder 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
•	☐ All b)☐ Some * c)☐ None of:						
	1. Certified copies of the priority documents						
2. Certified copies of the priority documents have been received in Application No							
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
2) 🔲 Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal I	v (PTO-413) Paper No(s) Patent Application (PTO-152)				

Application/Control Number: 09/533,219

Art Unit: 1624

#### **DETAILED ACTION**

Applicant's amendment filed on 6-12-01 has been considered. Although applicant's argument has overcome the 103 rejection, the issue of double patenting remains outstanding. Furthermore, it is noted that a "Scope of Enablement" rejection should have been made on the method claims previously. Thus, while the 103 rejection is withdrawn, the rejection of double patenting is maintained, and a new 112 rejection is presented herein.

Claims 9, 11, 12, 14,16-19, 21, and 22 are pending for consideration.

# Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

1. Claims 11, 12, and 14 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the treatment of conditions responsive to thyromimetic activity, cardiovascular conditions, obesity, osteoporosis, etc., does not reasonably provide enablement for the **prevention** of said conditions. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. Nothing in the specification teaches how to prevent or when to prevent the claimed conditions. Bioassays were done for the binding of T<sub>3</sub>,

'Application/Control Number: 09/533,219

Art Unit: 1624

and lowering of cholesterol only. Thus, one skilled in the art would have to carry out undue experimentation to prevent all the claimed conditions using the compound recited in claim 9.

### Double Patenting

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

- 2. Claims 9, 11, 12, 14, 16-19, 21, and 22 remain provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 9, 11, 12, 14 and 16-20 of copending Application No. 09/702,634. Although the conflicting claims are not identical, they are not patentably distinct from each other for reasons stated in the last office action.
- 3. Claims 9, 11, 12, 14, 16-19, 21, and 22 remain provisionally rejected under the judicially created doctrine of **non-obviousness type** double patenting over claims 1-8, 10, 13, and 15 of copending Application No. 09/702,634. This is a provisional double patenting rejection since the conflicting claims have not yet been patented.

The subject matter claimed in the instant application is fully disclosed in the referenced copending application and would be covered by any patent granted on that copending application since the referenced copending application and the instant application are claiming common subject matter, as pointed out in the previous office action.

Furthermore, there is no apparent reason why applicant would be prevented from presenting claims corresponding to those of the instant application in the other copending

Art Unit: 1624

application. See *In re Schneller*, 397 F.2d 350, 158 USPQ 210 (CCPA 1968). See also MPEP § 804.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

### Information Disclosure Statement

The provisional application 60/122,292 has been considered, but said application cannot be considered as a prior art because it is not in public domain. Thus, it should not be listed on the IDS.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tamthom N. Truong whose telephone number is 703-305-4485. The examiner can normally be reached on M-F (9:30-6:00).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached on 703-308-4716. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Mukund Shah
Supervisory Patent Examiner
Art Unit 1624

T. Truong

August 15, 2001